Replies to post #105153 on Biotech Values

[pollyvonwog]

Let's see. Sandoz earns 18.6% of gross sales for it normal run of the mill generic business. If M-Enox were to be reduced to a run of the mill generic and Momenta would receive 'single to low double digits royalties on sales'' it seems to me that Momenta would again be capturing in the area of 45% - 50% of the profits.

JBog, I've had enough. Talking to you is like talking to a character in a Kafka novel.